rs281864900
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000518.5(HBB):βc.126_129delβ(p.Phe42LeufsTer19) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000923 in 1,614,116 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (β β ).
Frequency
Genomes: π 0.000099 ( 0 hom., cov: 32)
Exomes π: 0.000092 ( 0 hom. )
Consequence
HBB
NM_000518.5 frameshift
NM_000518.5 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 8.66
Genes affected
HBB (HGNC:4827): (hemoglobin subunit beta) The alpha (HBA) and beta (HBB) loci determine the structure of the 2 types of polypeptide chains in adult hemoglobin, Hb A. The normal adult hemoglobin tetramer consists of two alpha chains and two beta chains. Mutant beta globin causes sickle cell anemia. Absence of beta chain causes beta-zero-thalassemia. Reduced amounts of detectable beta globin causes beta-plus-thalassemia. The order of the genes in the beta-globin cluster is 5'-epsilon -- gamma-G -- gamma-A -- delta -- beta--3'. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
?
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most 50 bp of the penultimate exon, not predicted to undergo nonsense mediated mRNA decay. There are 247 pathogenic variants in the truncated region.
PM2
?
Very rare variant in population databases, with high coverage;
PP5
?
Variant 11-5226762-CAAAG-C is Pathogenic according to our data. Variant chr11-5226762-CAAAG-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 15417.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-5226762-CAAAG-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
HBB | NM_000518.5 | c.126_129del | p.Phe42LeufsTer19 | frameshift_variant | 2/3 | ENST00000335295.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
HBB | ENST00000335295.4 | c.126_129del | p.Phe42LeufsTer19 | frameshift_variant | 2/3 | 1 | NM_000518.5 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.000105 AC: 16AN: 152122Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
16
AN:
152122
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000278 AC: 70AN: 251398Hom.: 0 AF XY: 0.000339 AC XY: 46AN XY: 135860
GnomAD3 exomes
AF:
AC:
70
AN:
251398
Hom.:
AF XY:
AC XY:
46
AN XY:
135860
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000917 AC: 134AN: 1461876Hom.: 0 AF XY: 0.000117 AC XY: 85AN XY: 727246
GnomAD4 exome
AF:
AC:
134
AN:
1461876
Hom.:
AF XY:
AC XY:
85
AN XY:
727246
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.0000985 AC: 15AN: 152240Hom.: 0 Cov.: 32 AF XY: 0.000107 AC XY: 8AN XY: 74450
GnomAD4 genome
?
AF:
AC:
15
AN:
152240
Hom.:
Cov.:
32
AF XY:
AC XY:
8
AN XY:
74450
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:21Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:7
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 31, 2024 | This sequence change creates a premature translational stop signal (p.Phe42Leufs*19) in the HBB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HBB are known to be pathogenic (PMID: 23637309). This variant is present in population databases (rs281864900, gnomAD 0.2%). This premature translational stop signal has been observed in individuals with HBB-related conditions (PMID: 6826539, 25089872, 28635337). ClinVar contains an entry for this variant (Variation ID: 15417). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 03, 2021 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 20181291, 22975760, 6826539, 11224481, 24200214, 28635337, 26096776, 30487145, 30945812, 31111750, 31930713, 30275481, 10870880, 33198537, 8091935) - |
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Nov 04, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics and Genomics, Karolinska University Hospital | Aug 29, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Mar 22, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jan 06, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 21, 2023 | The HBB c.126_129del; p.Phe42LeufsTer19 variant (also known as Phe41fs when numbered from the mature protein or as codon 41/42-TTCT, rs80356821, HbVar ID: 849) has been reported in the homozygous and compound heterozygous states in individuals affected with beta(0) thalassemia (see link to HbVar, Kimura 1983). It is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 15417) and is observed in the general population at an overall frequency of 0.02% (73/282786 alleles) with increased frequency in the East Asian population (0.2%) in the Genome Aggregation Database. This variant creates a frameshift by deleting 4 nucleotides, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Link to HbVar: https://globin.bx.psu.edu/hbvar/hbvar.html Kimura A et al. Structural analysis of a beta-thalassemia gene found in Taiwan. J Biol Chem. 1983 Mar 10;258(5):2748-9. PMID: 6826539. - |
beta Thalassemia Pathogenic:5Other:1
Pathogenic, no assertion criteria provided | curation | The ITHANET community portal, The Cyprus Institute of Neurology and Genetics | Nov 25, 2019 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Mar 17, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 12, 2016 | Variant summary: The c.126_129delCTTT variant results in a premature termination codon, predicted to cause a truncated or absent HBB protein, which is a commonly known mechanism for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g.c.135delC, c.143_146dupATCT). Mutation taster predicts damaging outcome for this variant. This variant is found in 33/121370 control chromosomes at a frequency of 0.0002719, which does not exceed maximal expected frequency of a pathogenic allele (0.0111803). This variant is reported in the literatures as a well-known pathogenic variant predominantly identified in East and South Asian. In addition, multiple reputable databases classified this variant as pathogenic. Taken together, this variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 09, 2019 | NM_000518.4(HBB):c.126_129delCTTT(F42Lfs*19) is classified as pathogenic in the context of Hb beta chain-related hemoglobinopathy; it is associated with beta thalassemia and is classified as a beta-zero variant. Sources cited for classification include the following: PMID 6826539, 25000193, 6714226 and 25480500. Classification of NM_000518.4(HBB):c.126_129delCTTT(F42Lfs*19) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 31, 2018 | The HBB c.126_129delCTTT (p.Phe42LeufsTer19) variant, also described as codon 41/42 (-CTTT) or codon 41/42 (-TTCT), results in a frameshift and is predicted to result in premature truncation of the protein. This variant is particularly prevalent in the Chinese population and is usually associated with a beta-thalassemia phenotype (Lin et al. 2014; Zhang et al. 2015; Yu et al. 2015; Origa et al 2015). Across a selection of the available literature, the p.Phe42LeufsTer19 variant has been identified in a homozygous state in one individual and in a compound heterozygous state in seven individuals, all with beta-thalassemia (Kimura et al. 1983; Hernanda et al. 2012; Huang et al. 2014; Italia et al. 2015; Rujito et al. 2015). Control data are unavailable for this variant, which is reported at a frequency of 0.00496 in the East Asian population of the 1000 Genomes. Based on the evidence and the potential impact of frameshift variants, the p.Phe42LeufsTer19 variant is interpreted as pathogenic for beta-thalassemia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Beta-thalassemia HBB/LCRB Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | This variant c.126_129del (p.Phe42LeufsTer19) in HBB gene has been observed in the homozygous and compound heterozygous state in several individuals with HBB-related conditions (Kimura A et al., 1983). This sequence change creates a premature translational stop signal (p.Phe42Leufs*19) in the HBB gene. It is expected to result in an absent or disrupted protein product. This variant is present in the gnomAD database with a frequency of 0.03%. Loss-of-function variants in HBB are known to be pathogenic (Craig JE et al., 1994). This variant has been reported to the ClinVar database as Pathogenic. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Lifecell International Pvt. Ltd | - | A Heterozygous Frameshift variant c.126_129delCTTT in Exon 2 of the HBB gene that results in the premature termination of the protein (p.Phe42fs*19) was identified. The observed variant has a minor allele frequency of 0.00028% in gnomAD exomes and genomes, respectively. The severity of the impact of this variant on the protein is high, based on the effect ofthe protein and REVEL score . Rare Exome Variant Ensemble Learner (REVEL) is an ensembl method for predicting the pathogenicity of missense variants based on a combination ofscores from 13 individual tools: MutPred, FATHMM v2.3, VEST 3.0, PolyPhen-2, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP++, SiPhy, phyloP, and phastCons.The REVEL score for an individual missense variant can range from 0 to 1, with higher scores reflecting greater likelihood that the variant is disease-causing. The variant was found inClinVar (Variant ID :15417) with a classification of Pathogenic/Likely Pathogenic and a review status of (2 star) criteria provided, multiple submitters, no conflicts. The variant is reported in many patients with beta thalassemia (Chen W et al.,2010). Based on the above evidence this variant has been classified as Pathogenic according to the ACMG guidelines. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetics and Molecular Pathology, SA Pathology | Nov 04, 2021 | - - |
Beta zero thalassemia Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 28, 2002 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 25, 2015 | The c.126_129delCTTT pathogenic mutation (also known as codons 41/42 (-TTCT) and c.124_127delTTCT), located in coding exon 2 of the HBB gene, results from a deletion of 4 nucleotides between positions 126 and 129, causing a translational frameshift with a predicted alternate stop codon (p.F42Lfs*19). This mutation is associated with beta0-thalassemia and was originally reported as homozygous in a Chinese patient (Kimura A et al. J Biol Chem. 1983;258(5):2748-9). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
HBB-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 09, 2024 | The HBB c.126_129delCTTT variant is predicted to result in a frameshift and premature protein termination (p.Phe42Leufs*19). This variant was reported in individuals with beta-thalassemia (see for example Kazazian et al. 1984. PubMed ID: 6714226; Lau et al. 1997. PubMed ID: 9113933; Lin et al. 2021. PubMed ID: 34271589). This variant is reported in 0.23% of alleles in individuals of East Asian descent in gnomAD. Frameshift variants in HBB are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Fetal hemoglobin quantitative trait locus 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jan 01, 2019 | - - |
alpha Thalassemia;C0002895:Hb SS disease;C0019025:Hereditary persistence of fetal hemoglobin;C0700299:Heinz body anemia;C1840779:METHEMOGLOBINEMIA, BETA TYPE;C1858990:Dominant beta-thalassemia;C1970028:Malaria, susceptibility to;C4693822:Erythrocytosis, familial, 6;CN322236:Beta-thalassemia HBB/LCRB Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 08, 2022 | - - |
Hb SS disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at